Barclays PLC initiated coverage on shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) in a report issued on Wednesday. The firm issued an overweight rating and a $20.00 price objective on the biopharmaceutical company’s stock.

A number of other research firms also recently weighed in on SGMO. Wells Fargo & Company reiterated an outperform rating and set a $30.00 price target (up previously from $20.00) on shares of Sangamo Therapeutics in a research note on Tuesday, September 5th. Zacks Investment Research raised Sangamo Therapeutics from a hold rating to a buy rating and set a $14.00 price objective for the company in a report on Wednesday, November 15th. Jefferies Group LLC reissued a buy rating and set a $18.00 price objective on shares of Sangamo Therapeutics in a report on Thursday, September 14th. BidaskClub cut Sangamo Therapeutics from a buy rating to a hold rating in a report on Friday, July 28th. Finally, Piper Jaffray Companies raised Sangamo Therapeutics from a neutral rating to an overweight rating and set a $19.00 price objective for the company in a report on Wednesday, November 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $17.83.

Shares of Sangamo Therapeutics (NASDAQ SGMO) traded down $0.10 on Wednesday, reaching $15.00. 1,066,300 shares of the company traded hands, compared to its average volume of 1,293,673. Sangamo Therapeutics has a 52-week low of $2.65 and a 52-week high of $17.06. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The company had revenue of $11.81 million for the quarter, compared to analyst estimates of $10.37 million. During the same quarter last year, the firm posted ($0.27) earnings per share. The company’s quarterly revenue was up 333.0% compared to the same quarter last year. analysts predict that Sangamo Therapeutics will post -0.79 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Sangamo Therapeutics, Inc. (SGMO) Now Covered by Analysts at Barclays PLC” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/sangamo-therapeutics-inc-sgmo-now-covered-by-analysts-at-barclays-plc/1721895.html.

In other Sangamo Therapeutics news, Director Saira Ramasastry sold 5,000 shares of Sangamo Therapeutics stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $14.67, for a total value of $73,350.00. Following the completion of the sale, the director now directly owns 5,000 shares in the company, valued at $73,350. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director William R. Ringo sold 31,000 shares of Sangamo Therapeutics stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $14.37, for a total value of $445,470.00. Following the completion of the sale, the director now owns 31,800 shares of the company’s stock, valued at $456,966. The disclosure for this sale can be found here. Insiders sold 66,000 shares of company stock worth $972,570 over the last ninety days. 5.50% of the stock is currently owned by insiders.

Hedge funds have recently modified their holdings of the business. Parametric Portfolio Associates LLC purchased a new stake in Sangamo Therapeutics in the 1st quarter worth approximately $578,000. American International Group Inc. boosted its stake in shares of Sangamo Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 42,747 shares of the biopharmaceutical company’s stock worth $222,000 after acquiring an additional 2,818 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of Sangamo Therapeutics by 9.8% during the 1st quarter. Teachers Advisors LLC now owns 180,858 shares of the biopharmaceutical company’s stock worth $940,000 after acquiring an additional 16,130 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Sangamo Therapeutics by 8.4% during the 1st quarter. Vanguard Group Inc. now owns 3,087,650 shares of the biopharmaceutical company’s stock worth $16,056,000 after acquiring an additional 239,544 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Sangamo Therapeutics by 3.1% during the 1st quarter. Geode Capital Management LLC now owns 633,964 shares of the biopharmaceutical company’s stock worth $3,296,000 after acquiring an additional 19,331 shares in the last quarter. Institutional investors and hedge funds own 63.29% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.